Are Powell's Words A Sign Of Caution For This Office REIT? Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. In his words before Congress, Federal Reserve Chief Jerome Powell addressed an issue many real estate investors have been worried about for years: the ongoing fallout from commercial real estate. Powell defined the situation as "a risk that has been with us and will be with us for some time, probably for years." He emphasized that large banks recently passed their stress tests and that some stress tests focused on commercial real estate exposure. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? While most investors believe that large banks are too big to fail, much of the commercial real estate risk lies with smaller banks. For investors in office real estate investment trusts (REITs), finding out where the debt is situated and looking at the terms of that debt is essential. We expect REITs to carry debt, often more debt than other publicly traded companies, because of the rules for REITs that require them to distribute the bulk of their income in the form of dividends. While interest rates may drop in the future, much of the commercial real estate debt that exists was established before the pandemic when capital was still relatively cheap. To add fuel to the fire, much of that debt is due this year. Earlier this year, the Mortgage Bankers Association reported that $939 billion of the $4.7 trillion outstanding commercial mortgages was coming due this year. That works out to around 20%. Some of that may be refinanced, but when looking at REITs, a wide breadth of debt maturities is a reassuring sign that the company won't suddenly have to scramble to handle a looming debt issue. Can This Office REIT Rally? Boston Properties (NYSE:BXP) is a REIT with 187 properties, mostly offices but some life science facilities. As you might expect with a name like Boston Properties, much of its real estate is in the Boston market, but it also has exposure to New York, Seattle, San Francisco, Washington D.C., and Los Angeles. While its leased property rate is below what we'd like to see at 89.9%, that number has been dragged down by weakness in the Seattle, San Francisco, and Los Angeles markets. As of the first quarter, there are signs that the company can keep leasing new property. One encouraging note is that it has $1.2 billion worth of life science developments and redevelopment, 64% of which is preleased. Looking at its balance sheet, one point worth highlighting is that funds from operations (FFO) growth is anticipated to be in negative territory for the year, down to -3.3%, partly because of higher interest expense. When we dive deeper, we see that its net debt to EBITDA is rising, another sign of concern. Its debt-to-market capitalization has also been elevated in recent quarters. As of the first quarter, it was $15.4 billion, and the bulk (71.5%) was unsecured. Private credit offers up to 20% APY. Potential accredited investors are looking to capitalize on this growing asset class. Since the pandemic, Boston Properties hasn't raised its dividend, but it hasn't lowered it either, keeping it at a steady $0.98 per quarter or an annual dividend of $3.92. It has a forward dividend yield of 6.4%. While the stock price has dropped by over 53% during the past five years, what's interesting is that there is a wide variance in how analysts consider its prospects. The consensus price target is $81.14, but that takes into account target prices ranging from $52 to $132. Most recently, Morgan Stanley maintained its equal-weight rating. Jerome Powell's statement on Capitol Hill reminds all REIT investors that prudent debt management will be the key to success. Boston Properties has significant debt and a tough road ahead. Much will depend on whether its move into more life science properties attracts greater leasing volume. Investors may want to keep a close eye on its development pipeline to ensure it hits its leasing targets. Check Out One Of Benzinga's Top Picks for Private Market Opportunities Available Now: Integris Secured Credit Fund IV The fund provides a fixed annual return of 12%, payable quarterly, over a 2-year period starting April 2024 and ending April 2026. The note is secured by collateral with an estimated value of $71M, with an anticipated loan-to-value ratio of 14%. Minimum investment: $100,000 Available to: Accredited investors View fund information View more private market offerings on Benzinga's Alternative Investment screener. This article Are Powell's Words A Sign Of Caution For This Office REIT? originally appeared on Benzinga.com
Are Powell's Words A Sign Of Caution For This Office REIT?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...